Sanara Free Cash Flow Operating Cash Flow Ratio from 2010 to 2024

SMTI Stock  USD 35.94  0.42  1.16%   
Sanara Medtech's Free Cash Flow Operating Cash Flow Ratio is increasing with stable movements from year to year. Free Cash Flow Operating Cash Flow Ratio is predicted to flatten to 0.91. For the period between 2010 and 2024, Sanara Medtech, Free Cash Flow Operating Cash Flow Ratio quarterly trend regression had mean deviation of  0.19 and range of 0.8768. View All Fundamentals
 
Free Cash Flow Operating Cash Flow Ratio  
First Reported
2010-12-31
Previous Quarter
1.0817259
Current Value
0.91
Quarterly Volatility
0.25535814
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Sanara Medtech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sanara Medtech's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.9 M, Interest Expense of 499.6 K or Total Revenue of 68.2 M, as well as many indicators such as Price To Sales Ratio of 4.97, Dividend Yield of 0.0324 or PTB Ratio of 7.97. Sanara financial statements analysis is a perfect complement when working with Sanara Medtech Valuation or Volatility modules.
  
Check out the analysis of Sanara Medtech Correlation against competitors.
For more detail on how to invest in Sanara Stock please use our How to Invest in Sanara Medtech guide.

Latest Sanara Medtech's Free Cash Flow Operating Cash Flow Ratio Growth Pattern

Below is the plot of the Free Cash Flow Operating Cash Flow Ratio of Sanara Medtech over the last few years. It is Sanara Medtech's Free Cash Flow Operating Cash Flow Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sanara Medtech's overall financial position and show how it may be relating to other accounts over time.
Free Cash Flow Operating Cash Flow Ratio10 Years Trend
Pretty Stable
   Free Cash Flow Operating Cash Flow Ratio   
       Timeline  

Sanara Free Cash Flow Operating Cash Flow Ratio Regression Statistics

Arithmetic Mean1.14
Geometric Mean1.12
Coefficient Of Variation22.32
Mean Deviation0.19
Median1.02
Standard Deviation0.26
Sample Variance0.07
Range0.8768
R-Value0.21
Mean Square Error0.07
R-Squared0.04
Significance0.46
Slope0.01
Total Sum of Squares0.91

Sanara Free Cash Flow Operating Cash Flow Ratio History

2024 0.91
2023 1.08
2022 1.13
2021 1.16
2020 1.41
2019 1.79
2018 0.97

About Sanara Medtech Financial Statements

Investors use fundamental indicators, such as Sanara Medtech's Free Cash Flow Operating Cash Flow Ratio, to determine how well the company is positioned to perform in the future. Although Sanara Medtech's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Free Cash Flow Operating Cash Flow Ratio 1.08  0.91 

Currently Active Assets on Macroaxis

When determining whether Sanara Medtech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sanara Medtech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sanara Medtech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sanara Medtech Stock:
Check out the analysis of Sanara Medtech Correlation against competitors.
For more detail on how to invest in Sanara Stock please use our How to Invest in Sanara Medtech guide.
You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sanara Medtech. If investors know Sanara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sanara Medtech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.99)
Revenue Per Share
9.241
Quarterly Revenue Growth
0.352
Return On Assets
(0.05)
Return On Equity
(0.20)
The market value of Sanara Medtech is measured differently than its book value, which is the value of Sanara that is recorded on the company's balance sheet. Investors also form their own opinion of Sanara Medtech's value that differs from its market value or its book value, called intrinsic value, which is Sanara Medtech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sanara Medtech's market value can be influenced by many factors that don't directly affect Sanara Medtech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sanara Medtech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sanara Medtech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sanara Medtech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.